We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Genetics and Psychopathology in the 22q11 Deletion Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00161109
Recruitment Status : Unknown
Verified October 2004 by UMC Utrecht.
Recruitment status was:  Recruiting
First Posted : September 12, 2005
Last Update Posted : October 13, 2006
Information provided by:

Study Description
Brief Summary:

The purposes of this study are to:

  1. study the nature and longitudinal course of psychiatric symptoms in children with the 22q11.2 deletion syndrome and
  2. identify genes that contribute to the occurrence of these symptoms.

Condition or disease
Chromosome 22q11.2 Deletion Syndrome

  Show Detailed Description

Study Design

Study Type : Observational
Estimated Enrollment : 175 participants
Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Genetics and Psychopathology in the 22q11 Deletion Syndrome
Study Start Date : October 2002
Estimated Study Completion Date : October 2012

Groups and Cohorts

Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   8 Years to 20 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • 22q11.2 deletion confirmed with fluorescence in-situ hybridization (FISH)

Exclusion Criteria:

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00161109

Contact: Jacob AS Vorstman, M.D. 215 590 3863 J.A.S.Vorstman@azu.nl

United States, Pennsylvania
Children's Hospital of Philadelphia, Dpt of Genetics and Dpt of Child and Adolescent Psychiatry Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Jacob AS Vorstman, M.D.    215-590-2862    vorstman@email.chop.edu   
UMC Utrecht, Dpt of Child and Adolescent Psychiatry Recruiting
Utrecht, Netherlands, 3508 GA
Contact: Herman van Engeland, M.D., Ph.D.    +31 30 2506362    H.HaismaPieterse@umcutrecht.nl   
Sponsors and Collaborators
UMC Utrecht
Netherlands Brain Foundation
Children's Hospital of Philadelphia
Study Director: René S. Kahn, M.D., Ph.D. UMC Utrecht, The Netherlands
More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00161109     History of Changes
Other Study ID Numbers: P03.0377C
First Posted: September 12, 2005    Key Record Dates
Last Update Posted: October 13, 2006
Last Verified: October 2004

Keywords provided by UMC Utrecht:
22q11.2 deletion syndrome
Deletion size
Candidate genes
Psychiatric symptoms
Neuropsychological impairments
Psychophysiological performance

Additional relevant MeSH terms:
Craniofacial Abnormalities
DiGeorge Syndrome
22q11 Deletion Syndrome
Pathologic Processes
Musculoskeletal Abnormalities
Musculoskeletal Diseases
Heart Defects, Congenital
Cardiovascular Abnormalities
Cardiovascular Diseases
Heart Diseases
Lymphatic Abnormalities
Lymphatic Diseases
Abnormalities, Multiple
Congenital Abnormalities
Chromosome Disorders
Genetic Diseases, Inborn
Parathyroid Diseases
Endocrine System Diseases